全文获取类型
收费全文 | 3958篇 |
免费 | 292篇 |
国内免费 | 308篇 |
出版年
2024年 | 11篇 |
2023年 | 59篇 |
2022年 | 144篇 |
2021年 | 221篇 |
2020年 | 140篇 |
2019年 | 163篇 |
2018年 | 164篇 |
2017年 | 107篇 |
2016年 | 161篇 |
2015年 | 266篇 |
2014年 | 268篇 |
2013年 | 321篇 |
2012年 | 357篇 |
2011年 | 299篇 |
2010年 | 165篇 |
2009年 | 193篇 |
2008年 | 239篇 |
2007年 | 200篇 |
2006年 | 162篇 |
2005年 | 133篇 |
2004年 | 127篇 |
2003年 | 108篇 |
2002年 | 88篇 |
2001年 | 68篇 |
2000年 | 60篇 |
1999年 | 62篇 |
1998年 | 32篇 |
1997年 | 42篇 |
1996年 | 20篇 |
1995年 | 27篇 |
1994年 | 17篇 |
1993年 | 19篇 |
1992年 | 19篇 |
1991年 | 11篇 |
1990年 | 19篇 |
1989年 | 11篇 |
1988年 | 16篇 |
1987年 | 7篇 |
1986年 | 8篇 |
1985年 | 7篇 |
1984年 | 5篇 |
1983年 | 3篇 |
1982年 | 2篇 |
1981年 | 2篇 |
1979年 | 1篇 |
1974年 | 1篇 |
1969年 | 1篇 |
1949年 | 1篇 |
1948年 | 1篇 |
排序方式: 共有4558条查询结果,搜索用时 15 毫秒
141.
142.
143.
144.
Aidi injection (ADI), a traditional Chinese biomedical preparation, is a promising adjuvant therapy for gynecologic tumors (GTs), including cervical cancer (CC), endometrial cancer (EC), and ovarian cancer (OC). Although studies have reported positively on ADI therapy, its exact effects and safety in GT patients remain controversial. Therefore, a wide-ranging systematic search of electronic databases was performed for this meta-analysis. Data from 38 trials including 3309 GT patients were analyzed. The results indicated that the combination of conventional treatment and ADI markedly improved the patients’ overall response rate (P<0.00001), disease control rate (P<0.00001), and quality of life (P<0.05) compared with conventional treatment alone. Furthermore, patient immunity was enhanced with combined treatment, as indicated by significantly increased percentages of CD3+ (P=0.005) and CD4+ (P<0.00001) and increased CD4+/CD8+ ratio (P=0.001). Most of the adverse events caused by radiochemotherapy such as gastrointestinal issues, leukopenia, thrombocytopenia, and hepatotoxicity, (P<0.05 for all) were significantly alleviated when ADI was used in the GT patients. However, other adverse events such as nephrotoxicity, diarrhea, alopecia, and neurotoxicity did not significantly differ between the two groups. Overall, these results suggest that the combination of conventional and ADI treatment is more effective than conventional treatment alone. 相似文献
145.
146.
147.
148.
149.
Tarah A. Word Ann P. Quick Christina Y. Miyake Mayra K. Shak Xiaolu Pan Jean J. Kim Hugh D. Allen Martha Sibrian-Vazquez Robert M. Strongin Andrew P. Landstrom Xander H. T. Wehrens 《Journal of cellular and molecular medicine》2021,25(13):6115-6124
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited cardiac arrhythmia syndrome that often leads to sudden cardiac death. The most common form of CPVT is caused by autosomal-dominant variants in the cardiac ryanodine receptor type-2 (RYR2) gene. Mutations in RYR2 promote calcium (Ca2+) leak from the sarcoplasmic reticulum (SR), triggering lethal arrhythmias. Recently, it was demonstrated that tetracaine derivative EL20 specifically inhibits mutant RyR2, normalizes Ca2+ handling and suppresses arrhythmias in a CPVT mouse model. The objective of this study was to determine whether EL20 normalizes SR Ca2+ handling and arrhythmic events in induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) from a CPVT patient. Blood samples from a child carrying RyR2 variant RyR2 variant Arg-176-Glu (R176Q) and a mutation-negative relative were reprogrammed into iPSCs using a Sendai virus system. iPSC-CMs were derived using the StemdiffTM kit. Confocal Ca2+ imaging was used to quantify RyR2 activity in the absence and presence of EL20. iPSC-CMs harbouring the R176Q variant demonstrated spontaneous SR Ca2+ release events, whereas administration of EL20 diminished these abnormal events at low nanomolar concentrations (IC50 = 82 nM). Importantly, treatment with EL20 did not have any adverse effects on systolic Ca2+ handling in control iPSC-CMs. Our results show for the first time that tetracaine derivative EL20 normalized SR Ca2+ handling and suppresses arrhythmogenic activity in iPSC-CMs derived from a CPVT patient. Hence, this study confirms that this RyR2-inhibitor represents a promising therapeutic candidate for treatment of CPVT. 相似文献
150.
Xiangqin He Yanyan Yang Qi Wang Jueru Wang Shifang Li Chunrong Li Tingyu Zong Xiaolu Li Ying Zhang Yulin Zou Tao Yu 《Journal of cellular and molecular medicine》2021,25(14):7052-7065
Knowledge regarding the relationship between the molecular mechanisms underlying atherosclerosis (AS) and transfer RNA-derived small RNAs (tsRNAs) is limited. This study illustrated the expression profile of tsRNAs, thus exploring its roles in AS pathogenesis. Small RNA sequencing was performed with four atherosclerotic arterial and four healthy subject samples. Using bioinformatics, the protein-protein interaction network and cellular experiments were constructed to predict the enriched signalling pathways and regulatory roles of tsRNAs in AS. Of the total 315 tsRNAs identified to be dysregulated in the AS group, 131 and 184 were up-regulated and down-regulated, respectively. Interestingly, the pathway of the differentiated expression of tsRNAs in cell adhesion molecules (CAMs) was implicated to be closely associated with AS. Particularly, tRF-Gly-GCC might participate in AS pathogenesis via regulating cell adhesion, proliferation, migration and phenotypic transformation in HUVECs and VSMCs. In conclusion, tsRNAs might help understand the molecular mechanisms of AS better. tRF-Gly-GCC may be a promising target for suppressing abnormal vessels functions, suggesting a novel strategy for preventing the progression of atherosclerosis. 相似文献